The Vasculitis Foundation (VF) is pleased to announce an exciting new initiative: Vasculitis-Building Outcomes, Leading Discoveries (V-BOLD), which combines three of the VF’s most critical programs: Fellowships, Vasculitis Centers, and Research. “The VF continues to transform the landscape for patients with vasculitis and providers taking care of them,” said Anisha…...
ACR/EULAR Classification Criteria for AAV Released
The American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) endorsed the ACR/EULAR classification criteria for ANCA-associated vasculitis (EGPA, GPA and MPA). The classification criteria were developed and validated by an international group of medical experts over the past 11+ years through the Diagnostic and Classification…...
Introducing Our 2020-2021 VCRC-VF Fellow: Alvise Berti, MD
Dr. Berti began his work in vasculitis while he was a medical student at Vita-Salute San Raffaele University in Milan, Italy. At the time, Dr. Berti recognized that vasculitis was not very well understood, and being both curious and motivated to further explore this group of diseases, he realized that…...
ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis
October 8. 2021 ChemoCentryx Announces FDA Approval of TAVNEOS™ (avacopan) in ANCA-Associated Vasculitis ChemoCentryx announced today that the U.S. Food and Drug Administration (FDA) has approved TAVNEOS (avacopan) as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), and specifically for granulomatosis with polyangiitis…...
New Handout Provides Family Planning and Birth Control Information
We are excited to introduce the release of our new handout designed for our patients who have questions about family planning and birth control. The two-page handout is intended to offer a reference for patients to use when talking with their health care providers about these important issues. The handout…...
